Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience

Diker O., AKTAŞ B. Y., Ak R., KÖYLÜ B., BAŞ O., TABAN H., ...Daha Fazla

FUTURE ONCOLOGY, cilt.18, ss.323-331, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18
  • Basım Tarihi: 2022
  • Doi Numarası: 10.2217/fon-2021-0303
  • Dergi Adı: FUTURE ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.323-331
  • Anahtar Kelimeler: adjuvant paclitaxel plus trastuzumab, APT trial, HER2-overexpressing breast cancer, node negative, real-life experience, PRIMARY THERAPY, JOINT ANALYSIS, FOLLOW-UP, CHEMOTHERAPY, WOMEN, SURVIVAL, OUTCOMES, TRIAL
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Lay abstract In oncology practice, there have been some efforts to avoid the toxicity of combination chemotherapies and reduce the amount of treatment given in recent decades. These strategies have been studied especially for patients with a specific subtype of early-stage breast cancer. We present the results from patients treated in our centers and discuss them in relation to the literature.